|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Relmada Therapeutics, Inc.
| | | Phone: | (646) 677-3853 | Year Established: | 2007 | Main Contact: | Sergio Traversa, PharmD, MBA, CEO & Interim CFO | | Other Contacts: | Richard M. Mangano, Ph.D., CSO
| |
| Company Description | Relmada Therapeutics (formerly Camp Nine and TheraQuest Biosciences) is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company has a deep and diversified portfolio of four lead products at different stages of development and an early stage pipeline of an additional four products. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. Relmada’s approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
The Company is currently developing LevoCap ER, an abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. | |
|
|
|
|
|